{
  "id": 2250112,
  "title": "Adaptive Biotechnologies director Robert Hershberg sells $748k in shares",
  "url": "https://urgent.news/2026/08/20/adaptive-biotechnologies-director-robert-hershberg-sells-748k-in",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-20T23:15:58.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/adaptive-biotechnologies-director-robert-hershberg-sells-748k-in-shares-93CH-4870630"
  },
  "original_language": "en",
  "account": null,
  "summary": "Director Robert Hershberg of Adaptive Biotechnologies Corp (NASDAQ: ADPT) sold 30,664 shares on August 18, 2026, totalling $748,208 in a series of two transactions. The shares were sold at weighted average prices of $24.39 and $24.41, respectively, with individual sale prices ranging from $24.38 to $24.44. This sale comes amid ADPT's stock trading near its 52-week high of $26.16, following a substantial 107% return over the past year. Despite this, the stock appears overvalued according to InvestingPro analysis. Prior to these sales, Hershberg had acquired 15,000 shares through stock option exercise at $6.32 per share, totaling $94,800. Post-transaction, he holds 46,683 shares of the company's common stock. Meanwhile, Adaptive Biotechnologies reported a mixed second-quarter performance, with a loss of $0.25 per share missing estimates and revenue of $71.6 million, up 22% from the previous year. The company's core business and clonoSEQ MRD test franchise showed robust growth. Analysts BTIG and Guggenheim have raised their price targets to $25, citing strong performance in key areas.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}